Cyteph secures vital funding for brain cancer immunotherapy phase 1 clinical trial
Posted: 26 May 2023 Cyteph, a spin-out biotechnology company from QIMR Berghofer Medical Research Institute, was last night awarded a $1.5m grant via the CUREator incubator. This grant signals an official launch milestone for the Company, supporting its…
Celebrating remarkable women in healthtech
Posted: 25 May 2023 On Friday 19 May 2023, BioMelbourne Network hosted 590 amazing industry professionals at Connecting Women Lunch – our premier event of the year – and acknowledged remarkable women in healthtech. A huge thank you…
4DMedical unveils VQ product at premier US lung conference
Posted: 24 May 2023 Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces a significant technological breakthrough and milestone in its product development strategy, with its CT-based ventilation-perfusion product (CT:VQ) progressing to a developmental…
Avecho enters strategic partnership with Arthur Group, licensing TPM for development of enhanced cancer drugs
Posted: 23 May 2023 Avecho Biotechnology Limited has today announced it has secured a licensing and development agreement with Arthur Group, entering a strategic partnership for the development of a series of cancer drugs solubilised using TPM®. Avecho…
Study results show new Sofra drug reduces inflammation
Posted: 23 May 2023 Innovative biotech company Noxopharm Limited announces a new preclinical product candidate from its Sofra™ technology platform has shown effectiveness against inflammatory skin disease in preclinical models. In research presented at the 15th International Congress…
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Posted: 23 May 2023 Immutep Limited a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that efti, a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co.,…
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Posted: 23 May 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage…
Artificial Intelligence powers second-skin-like wearable tech
Posted: 23 May 2023 A new ultra-thin skinpatch with nanotechnology able to monitor 11 human health signals has been developed by researchers at Monash University. Researchers from the Faculty of Engineering and Faculty of Information Technology combined nanotechnology…
New Centre for Advanced Defence Research and Enterprise established
Posted: 23 May 2023 A Centre for Advanced Defence Research and Enterprise (CADRE-OCE) to develop new concepts and technologies to protect Defence personnel, first responders and the general community has been launched at the University of Melbourne. The…
Amplia receives grant to collaborate with CSIRO
Posted: 23 May 2023 Amplia Therapeutics Limited, is pleased to announce it has received grant funding to undertake a research collaboration with Australia’s national science agency CSIRO to develop novel topical formulations of the Company’s FAK inhibitors. Amplia…
Clue to age-related muscle wasting may lie in killifish
Posted: 23 May 2023 As we age, our muscles start to waste. Called sarcopenia, it happens to us all if we live long enough, but no one has ever understood why it happens. Now new research from the Australian…
Optiscan oral study published in prestigious medical journal
Posted: 23 May 2023 Optiscan Imaging Limited (ASX: OIL) is pleased to announce the publication of readout results of its oral cancer imaging study conducted by Dr. Camile Farah and his team at the Australian Centre for Oral…
